KDKhoa Manh Dinh

Khoa Manh Dinh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Khoa Manh Dinh has a total of 453 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Weight change and short-term risk of hypertension in healthy adults

    by Line H S Nielsen, Bertram Kjerulff, Camilla S Morgen, Jutta K H Skau, Martin Hey-Mogensen, Zahra McVey, Susan Mikkelsen, Kathrine A Kaspersen, Ole Frøbert, Lotte A Hindhede, et al.

    Aims: Obesity is a major risk factor for hypertension, but most evidence relies on single weight measurements. We examined associations between weight change and short-term risk of incident hypertension across body mass index (BMI) categories. Methods and results: We conducted a retrospective cohort study in the Danish Blood Donor Study of 81 954 participants aged 18–79 with at least two questionnaires (2010–2025). Weight change was the percentage difference between consecutive self-reported weights, grouped as stable, 2.5–5, 5–10, or more than 10% loss or gain. Incident hypertension was defined as first redemption of antihypertensive drugs. Associations were estimated using multivariable Cox models. During a median follow-up of 1.66 years (IQR 0.79–2.88; maximum 3 years), 5503 participants initiated antihypertensive treatment. In BMI-stratified analyses, weight gain was associated with higher risk of initiation in all BMI categories, while weight loss was associated with lower risk only in overweight or obesity relative to stable weight. Across BMI categories using stable normal weight as reference, associations were stronger at higher BMI. More than 10% weight gain was associated with hazard ratios of 1.60 (95% CI 1.30–1.96) in normal weight, 2.44 (2.02–2.96) in overweight and 4.51 (3.57–5.70) in obesity. Hazard ratios were comparable across sex and age groups, although higher in younger men with obesity, while rates were highest in older participants. Conclusion: Weight gain was associated with higher risk of antihypertensive treatment across BMI categories compared with stable weight, whereas weight loss was inversely associated with initiation among adults with overweight or obesity.

  • Open Access

    Effect of Hormonal Contraceptives on Circulating Biomarkers of Inflammation, Chemotaxis, Angiogenesis, and Vascular Stress

    by Bertram Kjerulff, Khoa Manh Dinh, Jens Kjærgaard Boldsen, Ulrik Schiøler Kesmodel, Joseph Dowsett, Susan Mikkelsen, Lisette J. A. Kogelman, Maria Didriksen, Christina Mikkelsen, Jakob Bay, et al.

    Hormonal contraceptive (HC) use is known to be associated with elevated CRP levels. However, evidence on the effect of HC on several circulating inflammatory biomarkers in healthy humans is limited. The aim of this study was to examine the association between hormonal contraceptives and circulating biomarker levels and differential cell counts. A cross‐sectional observational study design with biomarker measurements from 4,160 healthy females was used, coupled with registered HC prescriptions. We compared 752 high and low dose combined oral contraceptive (COC) users, 77 progestin‐only pill users, 417 levonorgestrel intrauterine device users, 65 hormonal therapy users, and 1,523 post‐menopausal women with a control group of 1,326 women below 50 years. Repeated differential cell counts from a different dataset of 16,231 females were analyzed for the effects of HC. Data were analyzed using various regression models. COC use was associated with higher vascular marker levels but lower chemokine levels. We found no association with progestin‐only use. The association with differential cell counts was limited for most HC types. This study emphasizes the widespread impact of HC on the immune and vascular systems and how the impact may differ between HC types. The biomarker associations found could be targets for elucidation in functional studies.


  • Open Access

    Multi-stage reweighting to correct for participation bias in a nationwide biobank with nested recruitment

    by Jacob Træholt, Maria Didriksen, Dorte Helenius, Lea A. N. Christoffersen, Khoa M. Dinh, Joseph Dowsett, Christina Mikkelsen, Lotte Hindhede, Liam J. E. Quinn, Mie T. Bruun, et al.

    A bstract: Selective participation in biobanks often compromises inference to the general population, particularly when selection occurs across multiple stages, whether at recruitment or during subsequent participation. Inverse probability (IP) weighting can reduce systematic differences using suitable external benchmarks, but most applications assume a single selection process. Here, we present a multi-stage IP-weighting framework and apply it to the Danish Blood Donor Study (DBDS), a nationwide biobank embedded in Denmark’s blood-donation infrastructure. Using national registers, we estimated year-specific probabilities of (i) donation activity and (ii) DBDS enrolment conditional on donation activity, yielding two-stage inclusion weights for 169,893 participants. These weights reduced inclusion-associated imbalance across the 52 auxiliary variables in the probability models by 97.6% (median) and, despite strong health selection under donation-based recruitment, reduced relative-prevalence discrepancies across held-out prescription phenotypes by 69.7% (median). The effective sample size after weighting was 30,627 (18.0% of 169,893). Combining the inclusion weights with questionnaire-specific response weights across five DBDS questionnaires (>500 questions) produced the largest changes from unweighted to weighted responses for health behaviours and symptom severity, including tobacco and alcohol consumption, menstrual-pain severity, restless-legs severity, nocturia, sleep disturbance, and fatigue. These findings support multi-stage IP-weighting to improve population alignment in biobanks with staged selection.

  • Open Access

    Central role of glycosylation processes in human genetic susceptibility to SARS-CoV-2 infections with Omicron variants

    by Frank Geller, Xiaoping Wu, Vilma Lammi, Erik Abner, Jesse Tyler Valliere, Katerina Nastou, Angus Burns, Morten Rasmussen, Niklas Worm Andersson, Liam Quinn, et al.

    The host genetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have previously been studied based on cases from the earlier waves of the pandemic in 2020 and 2021, identifying 51 genomic loci associated with infection and/or severity. SARS-CoV-2 has shown rapid sequence evolution, increasing transmissibility, particularly for Omicron variants, which raises the question of whether this affected the host genetic factors. We performed a genome-wide association study of SARS-CoV-2 infection with Omicron variants, including more than 150,000 cases from four cohorts. We identified 13 genome-wide significant loci, of which only five were previously described as associated with SARS-CoV-2 infection. The strongest signal was a single nucleotide polymorphism in an intron of ST6GAL1, a gene affecting immune development and function, connected to three other associated loci (harboring MUC1, MUC5AC and MUC16) through O-glycan biosynthesis. Our study provides robust evidence for individual genetic variation related to glycosylation, translating into susceptibility to SARS-CoV-2 infections with Omicron variants.


  • Open Access

    Evaluating the lockdown-induced effect on respiratory viruses in blood donors during two COVID-19 waves: a retrospective cross-sectional observational study in Denmark

    by Khoa Manh Dinh, Kathrine Agergård Kaspersen, Jens Kjærgaard Boldsen, Lone Pødenphant, Ole Birger Pedersen, Svend Ellermann-Eriksen, Lise Tornvig Erikstrup, Christian Erikstrup

  • Open Access

    A structural deletion in the 3′ UTR of SLC11A2 is associated with altered iron status: Evidence from two large Danish cohorts

    by Nanna Brøns, Andreas Stribolt Rigas, Kathrine Agergård Kaspersen, Ole Birger Pedersen, Christian Erikstrup, Thomas Folkmann Hansen, Erik Sørensen, Joseph Dowsett, Christina Mikkelsen, Lea Arregui Nordahl Christoffersen, et al.

    Summary: The SLC11A2 gene encodes divalent metal transporter 1, a key mediator of cellular and intestinal iron transport. While ultra‐rare pathogenic variants in SLC11A2 cause autosomal recessive anaemia with iron overload, the phenotypic consequences of structural variation in this gene remain unexplored. We investigated the impact of a recently identified structural deletion in the 3′ untranslated region ( SLC11A2 ‐Δ3.5kb) using genetic, biomarker and registry data from two large Danish cohorts: the Danish Blood Donor Study and the Copenhagen Hospital Biobank (CHB). Among 4847 heterozygous carriers and 320 633 non‐carriers, SLC11A2 ‐Δ3.5kb was associated with lower ferritin levels in both sexes and increased risk of iron deficiency in women. In female donors, SLC11A2 ‐Δ3.5kb was associated with lower haemoglobin levels, increased risk of donation deferral due to low haemoglobin and increased use of prescribed iron treatment. In male CHB participants carrying HFE variants, concurrent SLC11A2 ‐Δ3.5kb carriage was associated with a 66% reduced risk of iron overload, suggesting a potential disease‐modifying role in haemochromatosis. No associations were observed with cardiometabolic, inflammatory, neurological or malignant diseases. These findings suggest that SLC11A2 ‐Δ3.5kb affects iron homeostasis through reduced systemic iron availability and may have clinical relevance for personalised iron deficiency risk assessment and haemochromatosis penetrance.


  • Open Access

    Cohort profile: Copenhagen Hospital Biobank-chronic inflammatory disease—inflammatory bowel disease (CHB-CID:IBD) genetic cohort

    by Behrooz Darbani, Thorsten Brodersen, Anette Liljensøe, Signe Bek Sørensen, Josephine Bjergbæk Olsson-Svendsen, Alfonso Buil, Ahmed Kamal, Andrew J. Schork, Anja Poulsen, Bertram Dalskov Kjerulff, et al.

    The Copenhagen Hospital Biobank-chronic inflammatory disease—inflammatory bowel disease (CHB-CID: IBD) cohort contributes to genetic research in inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Of the 327,084 enrolled and genotyped individuals in the cohort, 10,626 have been diagnosed with IBD as of May 2023. The CHB-CID: IBD cohort includes both patients without IBD and healthy blood donors as control groups. Clinical data is collected from Danish registries and patient records, including details on hospital contacts, co-morbidities, medication, surgical procedures, and laboratory investigations. The cohort features a wide age range (> 18 years), extensive population coverage representative of Danish adults, and validated IBD diagnoses. Finally, the cohort benefits from continuous recruitment and regular updates of clinical information. The aim is to enhance IBD management and ultimately improve patients’ quality of life.


  • Open Access

    Evaluating infection risk associated with Staphylococcus aureus nasal carriage in blood donors: a prospective multicentre study in Denmark

    by Khoa Manh Dinh, Kathrine Agergård Kaspersen, Jens Kjærgaard Boldsen, Svend Ellermann-Eriksen, Sisse Rye Ostrowski, Bitten Aagaard, Henrik Hjalgrim, Ole Birger Pedersen, Lise Tornvig Erikstrup, Christian Erikstrup


  • Open Access

    Gastrointestinal symptoms and bowel habits in 53 046 healthy Danish blood donors: a nationwide cross-sectional study

    by Anne Karmisholt Grosen, Jens Kjærgaard Boldsen, Susan Mikkelsen, Simon Mark Dahl Baunwall, Jens Frederik Dahlerup, Khoa Manh Dinh, Mie Topholm Bruun, Bitten Aagaard, Christina Mikkelsen, Janna Nissen, et al.

    Objective: To characterise gastrointestinal symptoms and bowel habits in healthy blood donors and explore symptom phenotypes and their associated factors. Methods: Between November 2020 and March 2023, 53 046 participants in the nationwide Danish Blood Donor Study completed a questionnaire including 13 gastrointestinal symptoms, defaecation pattern regularity, stool frequency, and stool consistency. We used a data-driven approach to explore symptom phenotypes and investigated associated factors by multinomial logistic regression. Results: Among the 53 046 participants (52% women), 68% (95% CI 67.5% to 68.3%) reported at least one of 13 gastrointestinal symptoms. The most frequent symptoms were bloating (40%), abdominal rumbling (40%), abdominal pain (17%), acid regurgitation (13%), heartburn (12%), diarrhoea (12%), nausea (12%), and constipation (10%). Half of the participants (50%) had a regular defaecation pattern (defined as generally the same stool consistency and stool frequency) consisting of Bristol Stool Form Scale 4 stools 1–3 times per day. Symptom phenotypes and their prevalence among 51 820 near-complete case participants were as follows: (1) no gastrointestinal symptoms (32%); (2) bloating and/or rumbling only (21%); (3) acid regurgitation and/or heartburn only (4%); (4) any other one or two symptoms (14%); (5) any three or four symptoms (18%); (6) any five or six symptoms (7%); (7) at least seven symptoms (3%). The acid regurgitation and/or heartburn only phenotype associated with obesity, and the remaining symptomatic phenotypes were associated with female sex, decreasing age, and an irregular defaecation pattern, even after excluding individuals with self-reported irritable bowel syndrome, lactose intolerance, or gluten intolerance. Conclusion: Most healthy adults, especially women younger than 50 years, experience gastrointestinal symptoms. Symptom phenotypes strongly correlate with sex, age, and bowel habits.


  • Open Access

    Genome-wide associations spanning 194 in-hospital drug dosage change phenotypes highlight diverse genetic backgrounds in concurrent drug therapy

    by Alexander Pil Henriksen, Cristina Leal Rodríguez, Hannah Currant, Ioannis Louloudis, Jorge Hernansanz Biel, Maria Herrero-Zazo, Ewan Birney, Thomas Folkmann Hansen, Gianluca Mazzoni, Amalie Dahl Haue, et al.

    As populations get older and medicine consumption rises, the rate of concurrent drug use and polypharmacy among patients is increasing. Polypharmacy is known to complicate therapy and increase the risk of drug-drug interactions, the individuality of which remain largely unexplored. Here, we perform a series of genome-wide association studies to identify variants associated with dosage changes during episodes of concurrent drug therapy. We extracted in-hospital drug prescription records from 847,537 patients in a population-wide Danish hospital cohort. Using imputed genotype data from the Copenhagen Hospital Biobank and the Danish Blood Donor Study we then performed a series of genome-wide association analyses across 194 drug pair phenotypes fulfilling selection criteria. We identified 51 genome-wide significant (p < 5e-08) loci, 49 so far unreported in any genome-wide association studies, associated with dosage changes across 42 different drug pair phenotypes. 49 of the identified loci were unique to the respective drug pairs. Through annotation of the identified loci, expression quantitative trait loci analyses, and gene-based tests we found links to 57 distinct genes, several of which have previously been associated with disease. This study identifies genes that may modulate response to drug therapy in the context of polypharmacy. Our findings reveal distinct patterns of genetic variation across different drug pairs, suggesting a diverse set of genes involved in drug efficacy and drug response. This study may give a better understanding of the individuality of such mechanisms and may aid the development personalized treatment approaches.